N-[4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]-*N'*-(4-{4-[({[4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]amino}carbonyl)amino]phenoxy}phenyl)urea;

N,N"-*trans*-1,4-cyclohexylenebis{N'-[4-(4-amino-2-butyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)butyl]urea};

N,N'-bis(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)benzene-1,3-disulfonamide;

N,N'-bis(2-{2-[4-amino-2-(2-methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)terephthalamide;

N,N"-1,8-octanediylbis[N'-(2-{2-[4-amino-2-(methoxyethyl)-1*H*-imidazo[4,5-*c*]quinolin-1-yl]ethoxy}ethyl)urea]; and

1-[10-(4-amino-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinolin-1-yl)decyl]-2-ethoxymethyl-1*H*-imidazo[4,5-*c*]quinoline-4-amine;

or a pharmaceutical acceptable salt thereof.

18. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 and a pharmaceutically acceptable carrier.

19. A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 17 and a pharmaceutically acceptable carrier.

of interferon or tumor necrosis factor

EX-A

20. A method of inducing ~~cytokine~~ biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 1 to the animal.

21. The method of claim 20 wherein the compound or salt is administered topically.

~~of [illegible] HF~~ of interferon or tumor necrosis factor

EX-A

22. A method of inducing ~~cytokine~~ biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 17 to the animal.

23. The method of claim 22 wherein the compound or salt is administered topically.

24. A method of treating a viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.

25. The method of claim 24 wherein the compound or salt is administered topically.

26. A method of treating a viral disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 17 to the animal.

27. The method of claim 26 wherein the compound or salt is administered topically.

28. A method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.

29. The method of claim 28 wherein the compound or salt is administered topically.

30. A method of treating a neoplastic disease in an animal comprising administering a therapeutically effective amount of a compound or salt of claim 17 to the animal.

31. The method of claim 30 wherein the compound or salt is administered topically.

32. A compound of Formula (II):



(II)

wherein:

A_1 is a divalent linking group selected from the group consisting of:

straight or branched chain C_{4-20} alkylene;

straight or branched chain C_{4-20} alkenylene; and

straight or branched chain C_{4-20} alkynylene;

any of which may be optionally interrupted by $-S(O)_2-$ or a protected -C(O)-;

n is 0 to 4;

each R' present is independently selected from the group consisting of:

halogen;

alkyl;

alkenyl; and

-O-alkyl;

or a pharmaceutically acceptable salt thereof.

33. A compound of Formula (III):



(III)

wherein:

A_1 is a divalent linking group selected from the group consisting of:

straight or branched chain C_{4-20} alkylene;

straight or branched chain C_{4-20} alkenylene; and

straight or branched chain C_{4-20} alkynylene;

any of which may be optionally interrupted by $-S(O)_2-$ or a protected -C(O)-;

n is 0 to 4;

each R' present is independently selected from the group consisting of:

halogen;

alkyl;

alkenyl; and

-O-alkyl;

or a pharmaceutically acceptable salt thereof.

34. A compound of Formula (IV):



(IV)

wherein:

A_1 is a divalent linking group selected from the group consisting of:

straight or branched chain C_{4-20} alkylene;

straight or branched chain C_{4-20} alkenylene; and

straight or branched chain C_{4-20} alkynylene;

any of which may be optionally interrupted by $-S(O)_2-$ or a protected -C(O)-;

R" is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-substituted aryl;

-heteroaryl;

-substituted heteroaryl;

-alkyl-O-alkyl;

-alkyl-O-aryl;

-alkyl-O- alkenyl; and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$C(O)$-$N(R_6)_2$;

-$C(S)$-$N(R_6)_2$;

-$S(O)_2$-$N(R_6)_2$;

-$N(R_6)$-$C(O)$-$C_{1\text{-}10}$ alkyl;

-$N(R_6)$-$C(S)$-$C_{1\text{-}10}$ alkyl;

-$N(R_6)$- $S(O)_2$-$C_{1\text{-}10}$ alkyl;

-$C(O)$-$C_{1\text{-}10}$ alkyl;

-$C(O)$-O-$C_{1\text{-}10}$ alkyl;

-N_3;

-aryl;

-substituted aryl;

-heteroaryl;

-substituted heteroaryl;

-heterocyclyl;

-substituted heterocyclyl;

-$C(O)$-aryl;

-$C(O)$-(substituted aryl);

-$C(O)$-heteroaryl; and

-$C(O)$-(substituted heteroaryl);

n is 0 to 4;

each R' present is independently selected from the group consisting of:

halogen;

alkyl;

alkenyl; and

-O-alkyl;

each R_6 is independently hydrogen or C_{1-10} alkyl;

or a pharmaceutically acceptable salt thereof.

35. A compound of Formula (V):



(V)

wherein:

A_1 is a divalent linking group selected from the group consisting of:

straight or branched chain C_{4-20} alkylene;

straight or branched chain C_{4-20} alkenylene; and

straight or branched chain C_{4-20} alkynylene;

any of which may be optionally interrupted by $-S(O)_2-$ or a protected -C(O)-;

R" is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-substituted aryl;

-heteroaryl;

-substituted heteroaryl;

-alkyl-O-alkyl;

-alkyl-O-aryl;

-alkyl-O- alkenyl; and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

$-C(O)-N(R_6)_2$;

-C(S)N(R_6)$_2$;

-S(O)$_2$-N(R_6)$_2$;

-N(R_6)-C(O)-C_{1-10} alkyl;

-N(R_6)-C(S)-C_{1-10} alkyl;

-N(R_6)- S(O)$_2$-C_{1-10} alkyl;

-C(O)-C_{1-10} alkyl;

-C(O)-O-C_{1-10} alkyl;

-N_3;

-aryl;

-substituted aryl;

-heteroaryl;

-substituted heteroaryl;

-heterocyclyl;

-substituted heterocyclyl;

-C(O)-aryl;

-C(O)-(substituted aryl);

-C(O)-heteroaryl; and

-C(O)-(substituted heteroaryl);

n is 0 to 4;

each R' present is independently selected from the group consisting of:

halogen;

alkyl;

alkenyl; and

-O-alkyl;

each R_6 is independently hydrogen or C_{1-10} alkyl;

or a pharmaceutically acceptable salt thereof.